JP2009512699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512699A5 JP2009512699A5 JP2008536688A JP2008536688A JP2009512699A5 JP 2009512699 A5 JP2009512699 A5 JP 2009512699A5 JP 2008536688 A JP2008536688 A JP 2008536688A JP 2008536688 A JP2008536688 A JP 2008536688A JP 2009512699 A5 JP2009512699 A5 JP 2009512699A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- concentration
- active substance
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006186 oral dosage form Substances 0.000 claims 20
- -1 phthalate ester Chemical class 0.000 claims 17
- 239000013543 active substance Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 12
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 12
- 229920000642 polymer Polymers 0.000 claims 12
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 9
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- 239000002904 solvent Substances 0.000 claims 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 6
- 239000001087 glyceryl triacetate Substances 0.000 claims 5
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 5
- 239000004014 plasticizer Substances 0.000 claims 5
- 229960002622 triacetin Drugs 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 4
- 229920002301 cellulose acetate Polymers 0.000 claims 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 4
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 4
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 4
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 4
- 239000011877 solvent mixture Substances 0.000 claims 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 2
- WBKYGCZSBGEBFP-UHFFFAOYSA-N 5-butoxy-3-butoxycarbonyl-3-hydroxy-5-oxopentanoic acid Chemical compound CCCCOC(=O)CC(O)(CC(O)=O)C(=O)OCCCC WBKYGCZSBGEBFP-UHFFFAOYSA-N 0.000 claims 2
- GOJCZVPJCKEBQV-UHFFFAOYSA-N Butyl phthalyl butylglycolate Chemical compound CCCCOC(=O)COC(=O)C1=CC=CC=C1C(=O)OCCCC GOJCZVPJCKEBQV-UHFFFAOYSA-N 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 2
- 239000011149 active material Substances 0.000 claims 2
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 claims 2
- 235000004626 essential fatty acids Nutrition 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000008297 liquid dosage form Substances 0.000 claims 2
- 239000003158 myorelaxant agent Substances 0.000 claims 2
- 235000015097 nutrients Nutrition 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- XRCRWCVBMHENNE-UHFFFAOYSA-N sym-di-n-butyl citrate Natural products CCCCOC(=O)CC(O)(C(O)=O)CC(=O)OCCCC XRCRWCVBMHENNE-UHFFFAOYSA-N 0.000 claims 2
- 229920001897 terpolymer Polymers 0.000 claims 2
- 239000001069 triethyl citrate Substances 0.000 claims 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 2
- 235000013769 triethyl citrate Nutrition 0.000 claims 2
- 125000005591 trimellitate group Chemical group 0.000 claims 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000001361 adipic acid Substances 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 230000003257 anti-anginal effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 230000003262 anti-osteoporosis Effects 0.000 claims 1
- 230000002141 anti-parasite Effects 0.000 claims 1
- 230000000648 anti-parkinson Effects 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 229960002708 antigout preparations Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 229940124433 antimigraine drug Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 239000003200 antithyroid agent Substances 0.000 claims 1
- 229940043671 antithyroid preparations Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000003177 cardiotonic effect Effects 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007370 cognitive improvement Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000003163 gonadal steroid hormone Substances 0.000 claims 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N n-Decanedioic acid Natural products OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000000014 opioid analgesic Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 150000003900 succinic acid esters Chemical class 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 150000003899 tartaric acid esters Chemical class 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/257,432 US20070092559A1 (en) | 2005-10-24 | 2005-10-24 | Liquid dosage forms having enteric properties of delayed and then sustained release |
| PCT/US2006/039761 WO2007050294A2 (en) | 2005-10-24 | 2006-10-11 | Liquid dosage forms having enteric properties of delayed and then sustained release |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009512699A JP2009512699A (ja) | 2009-03-26 |
| JP2009512699A5 true JP2009512699A5 (enExample) | 2009-11-26 |
Family
ID=37744211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536688A Pending JP2009512699A (ja) | 2005-10-24 | 2006-10-11 | 遅延放出とその後の持続放出の腸溶性を有する液体剤形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070092559A1 (enExample) |
| EP (1) | EP1940365A2 (enExample) |
| JP (1) | JP2009512699A (enExample) |
| CN (1) | CN101296690A (enExample) |
| WO (1) | WO2007050294A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| CN101489560B (zh) | 2006-04-26 | 2015-11-25 | 苏佩努斯制药公司 | 具有s形释放曲线的奥卡西平控释制剂 |
| US20100099696A1 (en) * | 2008-10-16 | 2010-04-22 | Anthony Edward Soscia | Tamper resistant oral dosage forms containing an embolizing agent |
| EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
| GB2477590A (en) * | 2010-02-05 | 2011-08-10 | Biocopea Ltd | A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
| CN110314152B (zh) * | 2018-11-27 | 2021-03-26 | 西安圣雪沙药物开发有限公司 | 一种布洛芬缓释微丸胶囊及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL148500B (nl) * | 1967-10-07 | 1976-02-16 | Scherer Gmbh R P | Depotgeneesmiddelen in capsulevorm. |
| GB1322306A (en) * | 1971-04-15 | 1973-07-04 | Meiji Seika Co | Stabilized antibiotic preparation and manufacturing process therefor |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| DE3500103C2 (de) * | 1985-01-04 | 1987-01-22 | R.P. Scherer GmbH, 6930 Eberbach | Pharmazeutische Zubereitung mit einem in Wasser und Verdauungssäften schwer löslichen Wirkstoff |
| US4708834A (en) * | 1986-05-01 | 1987-11-24 | Pharmacaps, Inc. | Preparation of gelatin-encapsulated controlled release composition |
| US4835186A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
| JPS649932A (en) * | 1987-07-01 | 1989-01-13 | Toyo Capsel Kk | Soft capsule preparation using newly combined component as the base |
| JPH082781B2 (ja) * | 1988-10-18 | 1996-01-17 | 嘉明 川島 | 中空顆粒状医薬及びその製法 |
| US5527545A (en) * | 1989-09-18 | 1996-06-18 | Recordati S.A. Chemical And Pharmaceutical Company | Liquid-suspension controlled-release pharmaceutical composition |
| IT1250654B (it) * | 1991-07-08 | 1995-04-21 | Farcon Ag | Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph. |
| US5723151A (en) * | 1995-11-06 | 1998-03-03 | Eastman Chemical Company | Cellulose acetate phthalate enteric coating compositions |
| IL123840A (en) * | 1996-06-19 | 2002-07-25 | Novartis Ag | Preparations containing cyclosporine |
| EP1003476B1 (en) * | 1997-08-11 | 2004-12-22 | ALZA Corporation | Prolonged release active agent dosage form adapted for gastric retention |
| US6191162B1 (en) * | 1998-05-28 | 2001-02-20 | Medical Research Institute | Method of reducing serum glucose levels |
| US6312713B1 (en) * | 1998-06-12 | 2001-11-06 | Bernard Korol | Polymer matrices for storage and sustained release of drugs and chemicals |
| US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
| US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| EP1140012B1 (en) * | 1998-12-17 | 2004-03-03 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| US6797283B1 (en) * | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US6635281B2 (en) * | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
| US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| JP4610687B2 (ja) * | 1999-11-15 | 2011-01-12 | コニカミノルタホールディングス株式会社 | 原稿読み取り装置 |
| US20040028744A1 (en) * | 2002-06-17 | 2004-02-12 | Sauwaluxana Tongaree | Mucoadhesive composition |
| WO2005025544A1 (en) * | 2003-09-11 | 2005-03-24 | Glykon Technologies Group, Llc | Enteric delivery of (-)-hydroxycitric acid |
| GB0403808D0 (en) * | 2004-02-20 | 2004-03-24 | Bioprogress Technology Ltd | Films for use as dosage forms |
-
2005
- 2005-10-24 US US11/257,432 patent/US20070092559A1/en not_active Abandoned
-
2006
- 2006-10-11 CN CNA2006800396750A patent/CN101296690A/zh active Pending
- 2006-10-11 WO PCT/US2006/039761 patent/WO2007050294A2/en not_active Ceased
- 2006-10-11 EP EP06816742A patent/EP1940365A2/en not_active Withdrawn
- 2006-10-11 JP JP2008536688A patent/JP2009512699A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009512699A5 (enExample) | ||
| US11207273B2 (en) | Method of making an L-menthol dosage form | |
| JP3902229B2 (ja) | 結腸デリバリー用の、多腸溶ポリマー被覆物を有する医薬投与形態 | |
| JP3902228B2 (ja) | 結腸デリバリー用の医薬投与形態 | |
| JP4172917B2 (ja) | 急速に効果を発揮し且つ効果的な血漿薬物濃度が急速に低下する制御放出性製剤 | |
| JP2020059755A5 (enExample) | ||
| CA2761947C (en) | Coated pharmaceutical capsule dosage form | |
| JP2017019858A5 (enExample) | ||
| JP2008540419A5 (enExample) | ||
| JP5592902B2 (ja) | 治療薬の徐放性組成物 | |
| KR20100014629A (ko) | 타크로리무스의 변형제형 | |
| JPH04501411A (ja) | 結腸選択的到達性を持つ経口医薬用製剤 | |
| JP2005510539A (ja) | 複数のコーティングを有する医薬剤形 | |
| JP2009512699A (ja) | 遅延放出とその後の持続放出の腸溶性を有する液体剤形 | |
| NZ232323A (en) | Water dispersible formulation of gemfibrozil | |
| CN103417544A (zh) | 甲氨叶酸复方制剂及其制备方法和用途 | |
| JP5443768B2 (ja) | 医薬品球状物 | |
| CN101411702A (zh) | 盐酸奈福泮萘普生钠复方缓释制剂及其制备方法 | |
| CN104274408A (zh) | 一种熔融包衣的速释药物微粒及其制备方法 | |
| WO1998022096A1 (en) | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery | |
| CN101647782A (zh) | 长春西汀口服自微乳化微丸及其制备和应用 | |
| CA2271560C (en) | Pharmaceutical dosage form for colonic delivery | |
| CN100336501C (zh) | 醋炎痛缓释性圆粒组成物及制备方法 | |
| TWI257312B (en) | The composition and method of preparing acemetacin retard pellet and its dosage form | |
| CN105796521B (zh) | 改进的阿莫西林迟释制剂 |